Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

NCT06501534 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.

NCT NCT06501534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06501534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 10, 2024
Completion date
January 9, 2025
Enrollment
84 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gout, hyperuricemia